ClinicalTrials.gg
CompletedNCT05619536Updated Oct 1, 2024Results posted

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

A Phase 1 interventional study of CD388 Injection and Saline placebo in Healthy, sponsored by Cidara Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Cidara Therapeutics Inc. (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when dosed by subcutaneous (SQ) administration as a single dose to healthy Japanese adult subjects.

Read the detailed description

This is a Phase 1, single-center, prospective, randomized, double-blind study of ascending single doses of CD388 Injection administered SQ to healthy Japanese adult subjects. The goals are to assess safety, tolerability, and pharmacokinetics (PK) of CD388.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Cidara Therapeutics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be of Japanese descent with Japanese parents and grandparents, as determined by subject's verbal report.
  2. Willing and able to provide written .
  3. Males and females 18 to 65 years of age, inclusive.
  4. A female subject must meet one of the following criteria:

    1. If of - agrees to use a highly effective, preferably user-independent method of (failure rate of \<1 percent per year when used consistently and correctly) for at least 30 days prior to screening and agrees to remain on a highly effective method until 7 months after last dose of study medication, whichever is longer. Examples of highly-effective methods of contraception include: abstinence from heterosexual intercourse; hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch); intrauterine device (with or without hormones); or a double barrier method (e.g., condom and spermicide).
    2. If a female of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion without reversal surgery) or in a menopausal state (at least 1 year without menses), as confirmed by follicle-stimulating hormone (FSH) levels (≥40 milli-International units [mIU]/milliliter [mL]).
  5. A woman of childbearing potential must have a negative highly sensitive serum pregnancy test (β-human chorionic gonadotropin) at screening and a negative urine pregnancy test on Day -1 before the first dose of study drug.
  6. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of at least 7 months after study drug administration.
  7. A male subject that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 7 months after the last dose of the study medication.
  8. Good health and without signs or symptoms of current illness.
  9. Normal clinical examination, including:

    1. No physical examination findings that an Investigator determines would interfere with interpretation of study results.
    2. Screening without abnormalities.
    3. (CrCL) ≥80 mL/minute as calculated using the Cockcroft-Gault equation.
    4. Negative urine screen for drugs of abuse and alcohol at screening and Day -1.
  10. Body weight ≥50 kilograms (kg) and (BMI; calculated as weight in kg divided by height in meters [m] squared) between 18.0 and 30.0 kg/m\^2, inclusive.
  11. Willing to refrain from strenuous physical activity that could cause muscle aches or injury, including contact sports, at any time from screening through 30 days after any dose of study drug.
  12. Subject has adequate venous access for blood collection.

Exclusion criteria

Exclusion Criteria:

  1. History of any or allergic reaction to zanamivir or other neuraminidase inhibitors (i.e., laninamivir, oseltamivir, peramivir), or to of the CD388 Injection drug formulation; or history of drug-induced exfoliative skin disorders (e.g., Stevens-Johnson syndrome [SJS], erythema multiforme, or toxic epidermal necrolysis [TEN]).
  2. History of any of the following:

    1. Allergies, anaphylaxis, skin rashes (foods such as milk, eggs, medications, vaccines, polyethylene glycol [PEG], etc.).
    2. Chronic immune-mediated disease, positive first-degree family history of diseases.
    3. Atopic dermatitis or psoriasis.
    4. Bleeding disorder.
    5. Psychiatric condition, seizures, hallucinations, anxiety, depression, or treatment for mental conditions.
    6. Migraines.
    7. Syncope, or vasovagal syndrome with injections or blood draws.
    8. Cardiac arrhythmia considered by the Investigator.
  3. Subjects with one or more of the following laboratory abnormalities at screening as defined by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1 (DAIDS 2017):

    1. Serum creatinine, Grade ≥1 (≥1.1 × [ULN]).
    2. Pancreatic amylase or lipase, Grade ≥2 (≥1.5 × ULN).
    3. (AST) or alanine aminotransferase (ALT), Grade ≥1 (≥1.25 × ULN).
    4. Total , Grade ≥1 (≥1.1 × ULN).
    5. Any other toxicity Grade ≥2, except for Grade 2 elevations of triglycerides, low density lipoprotein cholesterol, and/or total cholesterol.
    6. Any other laboratory abnormality considered to be clinically significant by the Investigator.

      • Note: Retesting of abnormal laboratory values that may lead to exclusion will be allowed once without prior asking approval from the Sponsor. Retesting will take place during a scheduled or unscheduled visit during screening. Subjects with a normal value at retest may be included.
  4. Alcohol or drug addiction in the past 2 years.
  5. Experiencing symptoms of acute illness or chronic disease within 14 days prior to clinical research unit (CRU) check-in.
  6. At screening, a positive result for virus surface antigen, virus antibody, or (HIV) antibody.
  7. A positive result at CRU check-in for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction (PCR).
  8. Unwilling to comply with local health policy effective at the time regarding coronavirus disease 2019 (COVID-19). Full COVID-19 vaccination prior to participation is strongly recommended.
  9. Women who are pregnant or nursing.
  10. Received any over-the-counter (OTC) medications or nutritional supplements within 7 days, or any prescription medications within 14 days or \<5 half-lives prior to dosing, whichever is longest (except for hormonal , acetaminophen, or ibuprofen).
  11. Current nicotine user or has quit habitual nicotine use in the 30 days prior to screening.
  12. Received any vaccines or immunoglobulins within 28 days prior to dosing (90 days in case of intravenous immunoglobulin [IVIg] or biologics, or 14 days for COVID-19 vaccine).
  13. Donated blood (within 56 days of screening) or plasma (within 7 days of screening) or experienced significant blood loss or significant blood draw (blood donation or blood loss ≥500 mL) when participating in non-interventional clinical trials within 30 days prior to dosing.
  14. Received a blood transfusion within 28 days prior to dosing.
  15. Received any biologics within 90 days prior to dosing; or previous participation in another study (including device studies) within 30 days of dosing or 5 half-lives of the study drug, whichever is longer, prior to screening (prior participation at any time in non-invasive methodology trials in which no drugs were given is acceptable).
  16. Previous treatment with CD388.
  17. Preplanned surgery at any time during the study.
  18. The Principal Investigator (PI) considers that the volunteer should not participate in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1

    9 subjects randomized in a 7:2 ratio to receive either 50 mg CD388 SQ injection or matching placebo injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 2

    9 subjects randomized in a 7:2 ratio to receive either 150 mg CD388 SQ injection or matching placebo injection

    Combination Product: CD388 Injection · Drug: Saline placebo

  • Experimental
    Cohort 3

    9 subjects randomized in a 7:2 ratio to receive either 450 mg CD388 SQ injection or matching placebo injection

    Combination Product: CD388 Injection · Drug: Saline placebo

Interventions

  • Combination productCD388 Injection

    CD388 liquid for injection

  • DrugSaline placebo

    Sterile normal saline for injection

06

What researchers measure

Primary outcomes

  1. Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

    Number of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

    Time frame: From Day 1 through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others)

  2. Severity of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

    Severity of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

    Time frame: From Day 1 through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration

    Evaluation of the maximum plasma concentration (Cmax) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

  2. Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration

    Evaluation of the time to maximum plasma concentration (Tmax) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

  3. Terminal Elimination Half-life (t½) Following CD388 Injection Administration

    Evaluation of the terminal elimination half-life (t½) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

  4. Apparent Clearance (CL/F) Following CD388 Injection Administration

    Evaluation of the apparent clearance (CL/F) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

  5. Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration

    Evaluation of the apparent volume of distribution (VZ/F) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

  6. Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-last]) Following CD388 Injection Administration

    Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-last\]) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

  7. Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration

    Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following subcutaneous administration of a single dose of CD388.

    Time frame: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

07

Results

Posted Oct 1, 2024

Participant flow

The planned total enrollment was 27 participants. One participant in the 150 milligram (mg) CD388 arm withdrew consent shortly after dosing and was replaced, resulting in an overall enrollment of 28 participants.

Participant flow — Overall Study
Milestone50 mg CD388150 mg CD388450 mg CD388Pooled Placebo
Started7876
Completed7665
Not completed0211
Withdrew: Withdrawal by subject0101
Withdrew: Lost to follow-up0110

Outcome measures

PrimaryNumber of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

Number of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Time frame:
From Day 1 through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others)
Reported as:
Number · events
Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388
events50 mg CD388150 mg CD388450 mg CD388Pooled Placebo
Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD3887362
PrimarySeverity of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388

Severity of TEAEs reported, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.

Time frame:
From Day 1 through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others)
Reported as:
Number · events
Severity of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388
events50 mg CD388150 mg CD388450 mg CD388Pooled Placebo
Grade 1 (Mild)7362
Grade 2 (Moderate)0000
Grade 3 (Severe)0000
SecondaryMaximum Plasma Concentration (Cmax) Following CD388 Injection Administration

Evaluation of the maximum plasma concentration (Cmax) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Mean · micrograms/milliliter (ug/mL)
Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration
micrograms/milliliter (ug/mL)Cohort 1Cohort 2Cohort 3
Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration3.87 ± 0.77613.5 ± 4.1041.7 ± 9.27
SecondaryTime to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration

Evaluation of the time to maximum plasma concentration (Tmax) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Median · hours (h)
Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration
hours (h)Cohort 1Cohort 2Cohort 3
Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration312.00 (192.00 to 313.03)97.00 (48.00 to 313.00)144.00 (72.00 to 312.02)
SecondaryTerminal Elimination Half-life (t½) Following CD388 Injection Administration

Evaluation of the terminal elimination half-life (t½) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Mean · hours (h)
Terminal Elimination Half-life (t½) Following CD388 Injection Administration
hours (h)Cohort 1Cohort 2Cohort 3
Terminal Elimination Half-life (t½) Following CD388 Injection Administration1325.86 ± 289.241284.26 ± 389.611210.10 ± 193.31
SecondaryApparent Clearance (CL/F) Following CD388 Injection Administration

Evaluation of the apparent clearance (CL/F) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Mean · liters/hour (L/h)
Apparent Clearance (CL/F) Following CD388 Injection Administration
liters/hour (L/h)Cohort 1Cohort 2Cohort 3
Apparent Clearance (CL/F) Following CD388 Injection Administration0.00653 ± 0.0005290.00723 ± 0.002000.00764 ± 0.00144
SecondaryApparent Volume of Distribution (VZ/F) Following CD388 Injection Administration

Evaluation of the apparent volume of distribution (VZ/F) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Mean · liters (L)
Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration
liters (L)Cohort 1Cohort 2Cohort 3
Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration12.5 ± 2.8712.6 ± 3.4213.3 ± 3.10
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-last]) Following CD388 Injection Administration

Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-last\]) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Mean · ug*h/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-last]) Following CD388 Injection Administration
ug*h/mLCohort 1Cohort 2Cohort 3
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-last]) Following CD388 Injection Administration5880 ± 61518900 ± 573053300 ± 8320
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration

Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following subcutaneous administration of a single dose of CD388.

Time frame:
At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)
Reported as:
Mean · ug*h/mL
Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration
ug*h/mLCohort 1Cohort 2Cohort 3
Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration7700 ± 65722200 ± 639060600 ± 10700

Adverse events

Collected over Adverse events were collected for all participants from the time of signing the informed consent form through the final study visit (Day 120 for the 50 mg dose arm; Day 165 for all others).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50 mg CD3880/7 (0%)0/7 (0%)7/7 (100%)
150 mg CD3880/8 (0%)0/8 (0%)3/8 (37.5%)
450 mg CD3880/7 (0%)0/7 (0%)7/7 (100%)
Pooled Placebo0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
Event50 mg CD388150 mg CD388450 mg CD388Pooled Placebo
FatigueGeneral disorders2/70/80/71/6
Injection site hemorrhageGeneral disorders0/70/82/70/6
Upper respiratory tract infectionInfections and infestations0/70/82/70/6
ConstipationGastrointestinal disorders1/71/80/71/6
Influenza like illnessGeneral disorders1/70/80/70/6
Asymptomatic COVID-19Infections and infestations1/70/81/70/6
COVID-19Infections and infestations1/71/80/70/6
HeadacheNervous system disorders1/70/81/70/6
RhinorrheaRespiratory, thoracic and mediastinal disorders0/70/81/70/6
Injection site erythemaGeneral disorders0/71/80/70/6

Baseline characteristics

The Safety Population analyzed consisted of all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
Mean51.4 ± 13.6050.4 ± 11.9046.0 ± 15.3549.8 ± 15.9949.4 ± 13.49
Age, Continuous
Age, Continuous(years)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
Median54.0 (22 to 62)55.0 (26 to 64)47.0 (21 to 65)54.5 (20 to 63)54.0 (20 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
Female532212
Male255416
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino787628
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
American Indian or Alaska Native00000
Asian787628
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
United States787628
Weight
Weight(kilograms (kg))50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
Mean62.84 ± 7.91769.71 ± 11.42173.27 ± 14.51768.55 ± 7.07368.64 ± 10.884
Weight
Weight(kg)50 mg CD388150 mg CD388450 mg CD388Pooled PlaceboTotal
Median61.50 (52.5 to 74.9)74.10 (51.8 to 84.9)77.10 (51.7 to 90.9)66.10 (61.1 to 77.6)67.15 (51.7 to 90.9)

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Altasciences Clinical Los Angeles, Inc.
    Cypress, California 90630, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jul 2023, 8 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Nov 17, 2022
StartActual
Oct 18, 2022
Primary completionActual
Jul 14, 2023
CompletionActual
Jul 14, 2023
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05619536
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Oct 18, 2022
Primary completion
Jul 14, 2023
Completion
Jul 14, 2023
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Ozlem Equils, MD
study director · Cidara Therapeutics Inc.
Youngjun Kim, MD
principal investigator · Altasciences Clinical Los Angeles, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion